

# Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drugs in Development, 2021

<https://marketpublishers.com/r/PE6FAF20759AEN.html>

Date: September 2021

Pages: 80

Price: US\$ 3,500.00 (Single User License)

ID: PE6FAF20759AEN

## Abstracts

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drugs in Development, 2021

### SUMMARY

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 21 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Prostaglandin E2 Receptor EP4 Subtype - Drugs In Development, 2021, outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 13 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Musculoskeletal Disorders, Respiratory, Women's Health, Gastrointestinal, Genetic Disorders and Undisclosed which include indications Colorectal Cancer, Gastric

Cancer, Solid Tumor, Autoimmune Disorders, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Rectal Cancer, Triple-Negative Breast Cancer (TNBC), Chronic Obstructive Pulmonary Disease (COPD), Endometriosis, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Osteoarthritis, Pain, Allergies, Asthma, Bladder Cancer, Bone Defects, Breast Cancer, Cervical Cancer, Colon Cancer, Delirium, Esophageal Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammatory Bowel Disease, Inflammatory Pain, Liver Cancer, Lung Adenocarcinoma, Melanoma, Metastatic Pancreatic Cancer, Muscle Invasive Bladder Cancer (MIBC), Neuroinflammation, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Pancreatic Cancer, Pneumonia, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sarcomas, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Unspecified and Unspecified Cancer.

Furthermore, this report also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)

The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects

The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Prostaglandin

E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -  
Overview

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -  
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -  
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -  
Companies Involved in Therapeutics Development

AskAt Inc

Domain Therapeutics SA

Eisai Co Ltd

Exalys Therapeutics Inc

GlaxoSmithKline Plc

Gurus BioPharm

Kaken Pharmaceutical Co Ltd

Kanaph Therapeutics Inc

Medibiofarma SL

Mesentech Inc

NB Health Laboratory Co Ltd

Ono Pharmaceutical Co Ltd

RaQualia Pharma Inc

Rottapharm Biotech Srl

Shanghai Bioray Laboratory Inc

Sosei Group Corp

TempestTx, Inc.

Teon Therapeutics Inc

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug

**Profiles**

AAT-008 - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

BYD-001 - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

CR-6086 - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

Drugs to Antagonize EP4 for Delirium and NeuroInflammation - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

DT-095895 - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

grapiprant - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

GSK-726701A - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

GUR-501 - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

KAG-308 - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

KNP-502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBF-251 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MES-1007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MES-1088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-4578 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palupiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize EP4 for Unspecified Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Prostanoid EP4 Receptor for Inflammatory Bowel Disease -  
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis -  
Drug Profile

Product Description

Mechanism Of Action

## R&D Progress

### TPST-1495 - Drug Profile

#### Product Description

#### Mechanism Of Action

## R&D Progress

### TT-038 - Drug Profile

#### Product Description

#### Mechanism Of Action

## R&D Progress

### Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -

#### Dormant Products

### Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -

#### Discontinued Products

### Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -

#### Product Development Milestones

#### Featured News & Press Releases

Aug 24, 2020: Adlai Nortye announces first patient dosed in phase 1b clinical trial of AN0025 (EP4 Antagonist) in combination with Merck's KEYTRUDA (pembrolizumab) for advanced solid tumors

Jan 30, 2020: Tempest Therapeutics announces FDA clearance of investigational new drug application for TPST-1495 and welcomes new investors

Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 (an Oral EP4 Antagonist) for locally advanced rectal cancer at ESMO 2019

May 07, 2019: Kyn Therapeutics strengthens leadership team with key appointments

Dec 20, 2018: Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007

Jul 19, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China

Apr 17, 2018: Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist

Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China

Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China

Dec 18, 2017: Investigational new drug application for EP4 antagonist AAT-007 was approved by the National Food and Drug Administration of the People's Republic of China

Sep 01, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Korea

Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress

Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at



the ESMO 2017 Congress

Jun 30, 2017: India Patent Office Granted AskAt a Substance Patent of EP4 antagonist(AAT-007)

Apr 25, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Japan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2021  
Number of Products under Development by Therapy Areas, 2021  
Number of Products under Development by Indications, 2021  
Number of Products under Development by Indications, 2021 (Contd..1)  
Number of Products under Development by Indications, 2021 (Contd..2)  
Number of Products under Development by Companies, 2021  
Products under Development by Companies, 2021  
Products under Development by Companies, 2021 (Contd..1)  
Products under Development by Companies, 2021 (Contd..2)  
Products under Development by Companies, 2021 (Contd..3)  
Products under Development by Companies, 2021 (Contd..4)  
Number of Products under Investigation by Universities/Institutes, 2021  
Products under Investigation by Universities/Institutes, 2021  
Number of Products by Stage and Mechanism of Actions, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Pipeline by AskAt Inc, 2021  
Pipeline by Domain Therapeutics SA, 2021  
Pipeline by Eisai Co Ltd, 2021  
Pipeline by Exalys Therapeutics Inc, 2021  
Pipeline by GlaxoSmithKline Plc, 2021  
Pipeline by Gurus BioPharm, 2021  
Pipeline by Kaken Pharmaceutical Co Ltd, 2021  
Pipeline by Kanaph Therapeutics Inc, 2021  
Pipeline by Medibiofarma SL, 2021  
Pipeline by Mesentech Inc, 2021  
Pipeline by NB Health Laboratory Co Ltd, 2021  
Pipeline by Ono Pharmaceutical Co Ltd, 2021  
Pipeline by RaQualia Pharma Inc, 2021  
Pipeline by Rottapharm Biotech Srl, 2021  
Pipeline by Shanghai Bioray Laboratory Inc, 2021  
Pipeline by Sosei Group Corp, 2021  
Pipeline by TempestTx, Inc., 2021  
Pipeline by Teon Therapeutics Inc, 2021  
Dormant Products, 2021

Dormant Products, 2021 (Contd..1)  
Discontinued Products, 2021  
Discontinued Products, 2021 (Contd..1)

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

## I would like to order

Product name: Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/PE6FAF20759AEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PE6FAF20759AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

